Back to today’s briefing

Story perspectives

Pitavastatin Cuts Cardiovascular Risk by 36% in HIV Patients

3/20/2025

47 10

Summary

Story summary

At CROI 2025 in San Francisco, Professor Steven Grinspoon revealed that pitavastatin slashed cardiovascular risk by 36% in HIV patients. The REPRIEVE trial highlighted its effectiveness in individuals with existing coronary plaque. Additionally, inflammation markers like hs-CRP and IL-6 were associated with cardiovascular events, underscoring the need for focused research on statin therapies.

1 of 1

Story summary

At CROI 2025 in San Francisco, Professor Steven Grinspoon revealed that pitavastatin slashed cardiovascular risk by 36% in HIV patients. The REPRIEVE trial highlighted its effectiveness in individuals with existing coronary plaque. Additionally, inflammation markers like hs-CRP and IL-6 were associated with cardiovascular events, underscoring the need for focused research on statin therapies.